We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The Paediatric Neurology Department at the Hospital Vall d’Hebron is specialised in the genetic diagnosis of childhood neurological diseases. It participates in different national and European reference networks (like the URDCat Project, Solve-RD, and the European Reference Network for Rare Neurological Diseases), which centralises a large number of paediatric patients with hereditary dystonia. The genetic studies are carried out in the Paediatric Neurology Laboratory as part of several different research studies, which are funded by national and international entities as well as associations of families affected by dystonia.
Patients who are likely to suffer from dystonia undergo different metabolic, neurophysiological, and neuroimaging tests in order to classify what kind of dystonia they have, before carrying out genetic studies. Next, DNA sequencing studies are performed to establish the genetic origin of the dystonia.
To determine the origin of the patient’s dystonia, which is essential for deciding on a correct course of treatment.
There are many different genetic origins of dystonia. Therefore, diagnosing it requires both conventional and newly developed DNA sequencing techniques.
For patients with myoclonus-dystonia, first, Sanger sequencing is done for the epsilon-sarcoglycan gene, which is responsible for 70% of myoclonus-dystonia cases in children.
For patients with other kinds of dystonia, whole-exome sequencing (on the parents and the patient) or sequencing for the index case (the patient) is done first, depending on the DNA samples available.
There are no risks for the patient.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.